SARS-CoV-2 nasopharyngeal viral load in individuals infected with BA.2, compared to Alpha, Gamma, Delta and BA.1 variants: A single-center comparative analysis

BACKGROUND: SARS-CoV-2 has evolved, leading to the emergence of new Variants Of Concern (VOCs) with significant impact on transmissibility. Although the transmission process is complex, higher nasopharyngeal viral load (NP-VL) can be considered as a proxy for greater transmissibility. OBJECTIVES: The aim of this analysis was to compare NP-VL across a set of representative VOCs observed in mildly symptomatic patients. STUDY DESIGN: Observational single-center comparative analysis of patients with early mild-to-moderate COVID-19, enrolled within the early treatment access program of Lazzaro Spallanzani Institute (March 2021-March 2022). NP-VL before drug administration was estimated through RT-PCR, based on cycle threshold values (CTs); VOCs were identified by Sanger sequencing. VOCs’ average treatment effect (ATE) was estimated on the CTs fitted in the log2 scale, controlling for potential confounders. RESULTS: A total of 707 patients were included. VOCs were: 10% Alpha, 3% Gamma, 34% Delta, 34% BA.1, 19% BA.2. Mean CTs for BA.1 and BA.2 were lower than Delta and BA.1, respectively. After adjusting for calendar time, age, immunodeficiency and vaccination, CTs for Gamma were lower than those seen for Alpha and higher than Delta, for Delta were similar to BA.1, for BA.2 were lower than Delta and BA.1. CONCLUSIONS: Our analysis shows higher NP-VL of BA.2 compared to previously circulating VOCs, even after controlling for factors potentially contributing to the amount of nasopharyngeal viral RNA, included vaccination, supporting the increased transmissibility of BA.2. Further studies are necessary to clarify this mechanism and to provide guidance for public health measures

Composition, age, and origin of the ~620 Ma Humr Akarim and Humrat Mukbid A-type granites: no evidence for pre-Neoproterozoic basement in the Eastern Desert, Egypt

The Humr Akarim and Humrat Mukbid plutons, in the central Eastern Desert of Egypt, are late Neoproterozoic post-collisional alkaline A-type granites. Humr Akarim and Humrat Mukbid plutonic rocks consist of subsolvus alkali granites and a subordinate roof facies of albite granite, which hosts greisen and Sn–Mo-mineralized quartz veins; textural and field evidence strongly suggest the presence of late magmatic F-rich fluids. The granites are Si-alkali rich, Mg–Ca–Ti poor with high Rb/Sr (20–123), and low K/Rb (27–65). They are enriched in high field strength elements (e.g., Nb, Ta, Zr, Y, U, Th) and heavy rare earth elements (Lan/Ybn = 0.27–0.95) and exhibit significant tetrad effects in REE patterns. These geochemical attributes indicate that granite trace element distribution was controlled by crystal fractionation as well as interaction with fluorine-rich magmatic fluids. U–Pb SHRIMP zircon dating indicates an age of ~630–620 Ma but with abundant evidence that zircons were affected by late corrosive fluids (e.g., discordance, high common Pb). eNd at 620 Ma ranges from +3.4 to +6.8 (mean = +5.0) for Humr Akarim granitic rocks and from +4.8 to +7.5(mean = +5.8) for Humrat Mukbid granitic rocks. Some slightly older zircons (~740 Ma, 703 Ma) may have been inherited from older granites in the region. Our U–Pb zircon data and Nd isotope results indicate a juvenile magma source of Neoproterozoic age like that responsible for forming most other ANS crust and refute previous conclusions that pre-Neoproterozoic continental crust was involved in the generation of the studied granites

RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies

Objective: The hypothesis that been set forward that use of Renin Angiotensin Aldosterone System (RAAS) inhibitors is associated with COVID-19 severity. We set-up a multicenter Italian collaboration (CORIST Project, ClinicalTrials.gov ID: NCT04318418) to retrospectively investigate the relationship between RAAS inhibitors and COVID-19 in-hospital mortality. We also carried out an updated meta-analysis on the relevant studies.Methods: We analyzed 4069 unselected patients with laboratory-confirmed SARS-CoV-2 infection and hospitalized in 34 clinical centers in Italy from February 19, 2020 to May 23, 2020. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received angiotensin-converting-enzyme inhibitors (ACEeI) or angiotensin-receptor blockers (ARB) with patients who did not. Articles for the meta-analysis were retrieved until July 13th, 2020 by searching in web-based libraries, and data were combined using the general variance-based method.Results: Out of 4069 COVID-19 patients, 13.5% and 13.3% received ACE-I or ARB, respectively. Use of neither ACE-I nor ARB was associated with mortality (multivariable hazard ratio (HR) adjusted also for COVID-19 treatments: 0.96, 95% confidence interval 0.77-1.20 and HR = 0.89, 0.67-1.19 for ACE-I and ARB, respectively). Findings were similar restricting the analysis to hypertensive (N = 2057) patients (HR = 1.00, 0.78-1.26 and HR = 0.88, 0.65-1.20) or when ACE-I or ARB were considered as a single group. Results from the meta-analysis (19 studies, 29,057 COVID-19 adult patients, 9700 with hypertension) confirmed the absence of association.Conclusions: In this observational study and meta-analysis of the literature, ACE-I or ARB use was not associated with severity or in-hospital mortality in COVID-19 patients